Sage Therapeutics Receives ‘Hold’ Recommendation from Brokerages

🌥️Trending News

Sage Therapeutics ($NASDAQ:SAGE), Inc., a leading pharmaceutical company, has recently received a “Hold” recommendation from brokerages at Defense World. A “Hold” recommendation indicates that while the stock may not present an immediate compelling value, it is still worth considering for an investor’s portfolio. Its portfolio includes drugs to treat severe neurological conditions such as seizures, depression, anxiety, and more. The company is known for its innovative approach to drug design and development, which has enabled them to bring new treatments to market that have made a significant impact on patients’ lives.

Additionally, Sage Therapeutics is also focused on advancing its existing pipeline of new treatments, and expanding its research into new areas of medicine. Despite recent strong performance in the stock market, Defense World brokerages have chosen to issue a “Hold” recommendation for Sage Therapeutics. While this may seem discouraging, it should be remembered that this recommendation does not mean that the stock is a bad option, but rather that investors should be mindful of any potential risks before making a decision. As the company continues to develop and bring new treatments to market, it may very well become a more attractive option for investors in the future.

Share Price

On Thursday, Sage Therapeutics received a ‘Hold’ recommendation from a number of brokerages as the stock opened at $47.9 before closing at $47.6, down by 0.3% from the previous closing price of 47.7. This is the latest in a string of ‘Hold’ recommendations from brokerages which have been consistently given to Sage Therapeutics for some time. The stock has yet to see any significant increase in value, and investors are uncertain as to what the future holds for the company. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Sage Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Sage Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Sage Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Sage Therapeutics are shown below. More…

Analysis

As GoodWhale, we have examined SAGE THERAPEUTICS‘s finances and how it stacks up on the Star Chart. We have concluded that SAGE THERAPEUTICS is strong in asset, growth, profitability, and weak in dividend. It is classified as ‘rhino’, a type of company we conclude that has achieved moderate revenue or earnings growth. Given these qualities, what type of investors may be interested in such company? In general, we believe SAGE THERAPEUTICS may be attractive to investors looking for moderate growth investments. They may find the company’s intermediate health score of 5/10 with regard to its cashflows and debt encouraging, as it indicates the company might be able to pay off debt and fund future operations. More…

Peers

The company has a strong focus on the development of novel therapies for the treatment of rare and orphan diseases. The company has a portfolio of products in various stages of development. The company’s products include Sage-547, an intravenous formulation of zolmitriptan for the treatment of migraines; Sage-217, an oral formulation of zolmitriptan for the treatment of cluster headaches; and Sage-689, an intranasal formulation of zolmitriptan for the treatment of migraines. The company is also developing product candidates for the treatment of Alzheimer’s disease, Parkinson’s disease, and epilepsy.

– Rocket Pharmaceuticals Inc ($NASDAQ:RCKT)

Rocket Pharmaceuticals Inc has a market cap of 1.48B as of 2022, a Return on Equity of -32.38%. The company focuses on the development and commercialization of innovative therapies for rare genetic diseases. The company’s mission is to provide hope to patients and their families by delivering life-changing treatments.

– Aileron Therapeutics Inc ($NASDAQ:ALRN)

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on the development of drugs for the treatment of cancer. Its lead product candidate is ALRN-6924, which is in Phase I clinical trials for the treatment of solid tumors and hematologic malignancies. Aileron Therapeutics Inc has a market cap of 305.62M as of 2022, a Return on Equity of -56.6%.

– CinCor Pharma Inc ($NASDAQ:CINC)

CinCor Pharma Inc is a pharmaceutical company with a market cap of 1.23B as of 2022 and a ROE of 78.34%. The company’s main focus is on the development and commercialization of treatments for cancer and other diseases. CinCor has a portfolio of products in various stages of development, including two products that are currently approved by the FDA. The company’s most advanced product is in Phase III clinical trials for the treatment of gastric cancer. CinCor is also developing a number of other products for the treatment of various cancers and other diseases.

Summary

Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing novel medicines to treat central nervous system (CNS) disorders. Analysts’ average recommendation for the stock is to “hold” as its share price has been volatile over the past few months.

However, the company has shown promising progress in the development of new treatments for neurological disorders like depression, anxiety, and Parkinson’s disease.

In addition, it has an impressive pipeline of other products in various stages of clinical development. Investors should consider monitoring the company’s progress in clinical trials and any new therapeutic options that may be developed as opportunities for investment. With the potential for new treatments to be developed, Sage Therapeutics could become a leader in the CNS market and provide investors with solid returns over the long term.